Skip to Content
  • The Real Numbers on Tamiflu

    I’ve been meaning to cover this controversy about Tamiflu (oseltamivir). The Cochrane group has reviewed all the clinical data obtainable on the drug̵… Read More
  • Merrimack Wins One

    You don’t get the chance to say “positive Phase III results in advanced pancreatic cancer” very often, but it looks like Merrimack Pharmaceuti… Read More
  • Google’s Big Data Flu Flop

    Some of you may remember the “Google Flu” effort, where the company was going to try to track outbreaks of influenza in the US by mining Google quer… Read More
  • Always Insist on Error Bars

    That’s the take-home of this post by Adam Feuerstein about La Jolla Pharmaceuticals and their kidney drug candidate GCS-100. It’s a galectin inhibit… Read More
  • Repurposing for Cervical Cancer

    One of the questions I was asked after my talk at Illinois was about repurposing drugs. I replied that there might be some opportunities there, but I didn’… Read More
  • More Good PD-1 News in Cancer

    PD-1 therapies are a big, big deal in oncology these days, and with results like this, no wonder. It’s a negative regulator of T-cell function, and blocki… Read More
  • A Call To Rein In Phase III Trials

    Here’s a very nice perspective on what gets funded in drug research and why. Robert Kocher and Bryan Roberts bring their venture-capital viewpoint (Venroc… Read More
Page 20 of 47« First...10...1819202122...3040...Last »